for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Soleno Therapeutics Inc

SLNO.OQ

Latest Trade

1.83USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

1.11

 - 

5.06

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.83
Open
--
Volume
--
3M AVG Volume
1.04
Today's High
--
Today's Low
--
52 Week High
5.06
52 Week Low
1.11
Shares Out (MIL)
31.79
Market Cap (MIL)
57.86
Forward P/E
-2.14
Dividend (Yield %)
--

Next Event

Soleno Therapeutics Inc at Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies

Latest Developments

More

Soleno Therapeutics Q2 Loss Per Share $0.31

Soleno Therapeutics Provides Update On Ongoing DESTINY PWS Phase III Trial Of DCCR In Prader-Willi Syndrome

Soleno Therapeutics Q1 Loss Per Share $0.22

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Soleno Therapeutics Inc

Soleno Therapeutics, Inc., formerly Capnia, Inc., is a healthcare company that develops and commercializes neonatology devices and diagnostics. The Company also has a therapeutics platform based on its proprietary technology for precision metering of gas flow. The Company offers products, such as CoSense end-tidal carbon monoxide (ETCO) Monitor, NeoPIP Infant Resuscitator and Accessories, and Serenz Nasal Relief. The Company has developed the CoSense End-Tidal Carbon Monoxide Monitor that measures ETCO for the detection of dangerous hemolysis rates. The Infant Solutions product line, including the NeoPIP Infant Resuscitator Unit and accessories, is designed for controlled and accurate resuscitation of neonates and infants in the clinical environment. Serenz Nasal Relief is a hand-held nasal irrigator that uses carbon dioxide (CO2) gas to wash the nasal passages.

Industry

Biotechnology & Drugs

Contact Info

1235 Radio Rd Ste 110

+1.650.2138444

http://www.capnia.com

Executive Leadership

Anish Bhatnagar

President, Chief Executive Officer, Interim Principal Financial and Accounting Officer, Director

Jonathan R. Wolter

Principal Financial and Accounting Officer

Anthony Wondka

Senior Vice President Research and Development

Ernest B. Mario

Chairman of the Board

Gwen A. Melincoff

Director

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-5.000

2017

-1.530

2018

-0.730

2019(E)

-0.850
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
4.18
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-60.48
Return on Equity (TTM)
-56.18

Latest News

BRIEF-Soleno Therapeutics Q1 Loss Per Share $0.19

* SOLENO THERAPEUTICS PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Soleno Therapeutics Says QTRLY Loss Per Share From Continuing Operations $0.17 - SEC Filing

* SOLENO THERAPEUTICS SAYS QTRLY LOSS PER SHARE FROM CONTINUING OPERATIONS $0.17 - SEC FILING

BRIEF-Soleno Therapeutics Announces Initiation Of Phase III Clinical Trial Of DCCR In Prader-Willi Syndrome

* SOLENO THERAPEUTICS ANNOUNCES INITIATION OF PHASE III CLINICAL TRIAL OF DCCR IN PRADER-WILLI SYNDROME

BRIEF-Soleno Therapeutics Reports Q4 Loss Per Share $0.43

* Q4 LOSS PER SHARE $0.39 FROM CONTINUING OPERATIONS Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Soleno Therapeutics Announces Successful End-Of-Phase II Meeting With FDA For DCCR In Prader-Willi Syndrome

* SOLENO THERAPEUTICS ANNOUNCES SUCCESSFUL END-OF-PHASE II MEETING WITH FDA FOR DCCR IN PRADER-WILLI SYNDROME

BRIEF-Soleno Therapeutics Files For Resale Of Up To 14.2 Mln Shares

* SOLENO THERAPEUTICS INC FILES FOR RESALE OF UP TO 14.2 MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING Source text: (http://bit.ly/2DKTA0l) Further company coverage:

BRIEF-Jack W. Schuler Living Trust Reports 13.4 Pct Stake In Soleno Therapeutics As Of December 15

* JACK W. SCHULER LIVING TRUST REPORTS 13.4 PERCENT STAKE IN SOLENO THERAPEUTICS INC AS OF DECEMBER 15 - SEC FILING Source text: (http://bit.ly/2mkVVHQ) Further company coverage:

BRIEF-Soleno Therapeutics Says Board Resolved To Decrease Size Of Board From Ten To Seven

* SOLENO THERAPEUTICS SAYS ON JAN 2, BOARD RESOLVED TO DECREASE SIZE OF BOARD FROM TEN DIRECTORS TO SEVEN DIRECTORS - SEC FILING Source text for Eikon: (http://bit.ly/2F27EUa) Further company coverage:

BRIEF-Birchview Capital LP Reports A 6.17 Pct Passive Stake In Soleno Therapeutics

* BIRCHVIEW CAPITAL LP REPORTS A 6.17 PCT PASSIVE STAKE IN SOLENO THERAPEUTICS AS OF DEC 15 - SEC FILING Source text for Eikon: (http://bit.ly/2DT2Zn3) Further company coverage:

BRIEF-Soleno Therapeutics Announces $15 Million Private Placement

* SOLENO THERAPEUTICS ANNOUNCES $15 MILLION PRIVATE PLACEMENT

BRIEF-Soleno Therapeutics Announces Joint Venture Agreement For Commercialization Of Cosense Monitoring Technology

* SOLENO THERAPEUTICS ANNOUNCES JOINT VENTURE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF COSENSE MONITORING TECHNOLOGY

BRIEF-Soleno Therapeutics posts Q3 loss $0.24/shr from continuing operations

* Soleno Therapeutics provides corporate update and reports third quarter 2017 financial results

BRIEF-Soleno Therapeutics regains compliance with Nasdaq listing requirements

* Soleno Therapeutics regains compliance with nasdaq listing requirements Source text for Eikon: Further company coverage:

BRIEF-Soleno Therapeutics announces 1-for-5 reverse stock split

* Soleno Therapeutics - reverse stock split of all of co's outstanding common shares at an exchange ratio of 1-for-5 will take effect on October 6, 2017 Source text for Eikon: Further company coverage:

BRIEF-Soleno Therapeutics receives scientific advice from EMA

* Soleno Therapeutics says has received scientific advice from CHMP of European Medicines Agency regarding diazoxide choline controlled-release for treatment of prader-willi syndrome

BRIEF-Soleno Therapeutics presents updated safety and efficacy data from clinical trial of DCCR for treatment of Prader-Willi syndrome

* Soleno Therapeutics presents updated safety and efficacy data from clinical trial of DCCR for treatment of Prader-Willi syndrome

BRIEF-Soleno Therapeutics issues new U.S. patent for DCCR in treatment of Prader-Willi syndrome

* Soleno Therapeutics announces issuance of new U.S. patent for DCCR in treatment of Prader-Willi syndrome

BRIEF-Soleno Therapeutics reports Q2 loss/share of $0.07

* Soleno Therapeutics provides corporate update and reports second quarter 2017 financial results

BRIEF-Soleno Therapeutics Q2 loss per share $0.07

* Soleno Therapeutics provides corporate update and reports second quarter 2017 financial results

BRIEF-Soleno Therapeutics announces sale of non-strategic assets to Flexicare Inc

* Soleno Therapeutics announces sale of non-strategic assets to Flexicare, Inc.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up